To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM

Summary

The goal of this Randomized controlled trials is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are: * major adverse cardiovascular events within 48 months of the trial duration * microvascular events within 48 months of the trial duration

Timeline

Start

2024-03-01

Primary completion

2027-02-01

Completion

2027-02-01

Publications

• Kim NH, Lee J, Chon S, Yu JM, Jeong IK, Lim S, Kim WJ, Song K, Cho HC, Yu HM, Kim KA, Kim SS, Lee SH, Kim CH, Kwak SH, Lee YH, Chung CH, Lee S, Jin HY, Lee JH, Koh G, Kim SY, Kim J, Lee JH, Kim TN, Jeon HJ, Lee JH, Jeon JH, Yoo HJ, Kim HK, Park HK, Nam-Goong IS, Hong S, Ahn CW, Yu JH, Park JH, Park KG, Park CH, Joung KH, Ryu OH, Park KY, Hong EG, Cha BS, Won KC, Chung YS, Kim SG. Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE). Endocrinol Metab (Seoul). 2024 Oct;39(5):722-731. doi: 10.3803/EnM.2024.1995. Epub 2024 Aug 22.

Drugs

Indications